Tue, October 10, 2017
Mon, October 9, 2017
Fri, October 6, 2017
Thu, October 5, 2017
Wed, October 4, 2017
Tue, October 3, 2017
Mon, October 2, 2017
Fri, September 29, 2017
Thu, September 28, 2017
Wed, September 27, 2017
Tue, September 26, 2017
Mon, September 25, 2017
Fri, September 22, 2017
Thu, September 21, 2017
Wed, September 20, 2017
Tue, September 19, 2017
Mon, September 18, 2017
Fri, September 15, 2017
Thu, September 14, 2017

Matthew Taylor Maintained (ABT) at Buy with Increased Target to $60 on, Sep 28th, 2017


//stocks-investing.news-articles.net/content/201 .. ith-increased-target-to-60-on-sep-28th-2017.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Matthew Taylor of Barclays, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $57 to $60 on, Sep 28th, 2017.

Matthew has made no other calls on ABT in the last 4 months.



There are 5 other peers that have a rating on ABT. Out of the 5 peers that are also analyzing ABT, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Amit Hazan of "Citigroup" Initiated at Hold and Held Target at $53 on, Thursday, August 17th, 2017
  • David Lewis of "Morgan Stanley" Maintained at Hold with Increased Target to $49 on, Monday, July 10th, 2017


These are the ratings of the 3 analyists that currently disagree with Matthew


  • Brittany Henderson of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $56 on, Friday, July 21st, 2017
  • David Toung of "Argus Research" Maintained at Strong Buy with Increased Target to $62 on, Friday, July 21st, 2017
  • Christopher Pasquale of "Guggenheim" Initiated at Strong Buy and Held Target at $58 on, Thursday, June 29th, 2017

Publication Contributing Sources